ICU Medical, Inc. (ICUI)

Market Cap	3.85B
Revenue (ttm)	2.34B
Net Income (ttm)	-111.01M
Shares Out	24.48M
EPS (ttm)	-4.57
PE Ratio	n/a
Forward PE	26.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	92,564
Open	159.99
Previous Close	160.96
Day's Range	157.03 - 161.98
52-Week Range	83.26 - 196.26
Beta	0.63
Analysts	Buy
Price Target	173.00 (+10.02%)
Earnings Date	Nov 12, 2024

About ICUI

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and elimina...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Mar 31, 1992
• Employees: 14,000
• Stock Exchange: NASDAQ
• Ticker Symbol: ICUI
• Website: https://www.icumed.com

Financial Performance

In 2023, ICU Medical's revenue was $2.26 billion, a decrease of -0.92% compared to the previous year's $2.28 billion. Losses were -$29.66 million, -60.08% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for ICUI stock is "Buy." The 12-month stock price forecast is $173.0, which is an increase of 10.02% from the latest price.

Price Target

$173.0

(10.02% upside)

Analyst Consensus: Buy